Skip to content

Celldex Therapeutics CLDX Gain/Loss on Asset Sales

Gain/Loss on Asset Sales at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-$160K

Other financials

Income statement

See full
Revenue$15.0K-97.8%
Operating income-$84.4M-34.6%
Net income-$78.7M-46.3%
EPS (diluted)-$1.18-45.7%

Balance sheet

See full
Cash & equivalents$35.7M+109%
Total debt$1.9M-44.3%
Total equity$456.2M-35.1%
Total assets$511.3M-30.9%

Cash flow

See full
Operating cash flow-$65.6M-20.6%
CapEx$1.6M+518%
Free cash flow-$67.2M-23.0%

Valuation

See full
Market cap$2.59B+75.2%
Enterprise value$2.55B+74.4%
P/S2,989.2×+2,794×

Profitability

See full
Operating margin-35,688.5%-39,114pp
Net margin-32,753.6%-35,519pp
FCF margin-26,125.8%-28,907pp

Returns & leverage

See full
Return on equity-48.9%-498pp
Debt / equity0.0×
Current ratio8.9×-12.7×

Where this comes from

Reported directly by Celldex Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:GainLossOnSaleOfPropertyPlantEquipment.

The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Celldex Therapeutics's gain/loss on asset sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Celldex Therapeutics's gain/loss on asset sales?
Celldex Therapeutics (CLDX) reported gain/loss on asset sales of -$3K in Q1 2026.
How has Celldex Therapeutics's gain/loss on asset sales changed year-over-year?
Celldex Therapeutics's gain/loss on asset sales increased by 25.0% year-over-year, from -$4K to -$3K.
What does gain/loss on asset sales mean?
Gains or losses on asset disposals removed from operating cash flow — the cash impact is captured in investing activities.